UNLABELLED: Keratins (K) 8 and 18 variants predispose carriers to the development of end-stage liver disease and patients with chronic hepatitis C to disease progression. Hepatocytes express K8/K18, whereas biliary epithelia express K8/K18/K19. K8-null mice, which are predisposed to liver injury, spontaneously develop anti-mitochondrial antibodies (AMA) and have altered hepatocyte mitochondrial size and function. There is no known association of K19 with human disease and no known association of K8/K18/K19 with human autoimmune liver disease. We tested the hypothesis that K8/K18/K19 variants associate with primary biliary cirrhosis (PBC), an autoimmune cholestatic liver disease characterized by the presence of serum AMA. In doing so, we analyzed the entire exonic regions of K8/K18/K19 in 201 Italian patients and 200 control blood bank donors. Five disease-associated keratin heterozygous variants were identified in patients versus controls (K8 G62C/R341H/V380I, K18 R411H, and K19 G17S). Four variants were novel and included K19 G17S/V229M/N184N and K18 R411H. Overall, heterozygous disease-associated keratin variants were found in 17 of 201 (8.5%) PBC patients and 4 of 200 (2%) blood bank donors (P < 0.004, odds ratio = 4.53, 95% confidence interval = 1.5-13.7). Of the K19 variants, K19 G17S was found in three patients but not in controls and all K8 R341H (eight patients and three controls) associated with concurrent presence of the previously described intronic K8 IVS7+10delC deletion. Notably, keratin variants associated with disease severity (12.4% variants in Ludwig stage III/IV versus 4.2% in stages I/II; P < 0.04, odds ratio = 3.25, 95% confidence interval = 1.02-10.40), but not with the presence of AMA. CONCLUSION: K8/K18/K19 variants are overrepresented in Italian PBC patients and associate with liver disease progression. Therefore, we hypothesize that K8/K18/K19 variants may serve as genetic modifiers in PBC.
UNLABELLED: Keratins (K) 8 and 18 variants predispose carriers to the development of end-stage liver disease and patients with chronic hepatitis C to disease progression. Hepatocytes express K8/K18, whereas biliary epithelia express K8/K18/K19. K8-null mice, which are predisposed to liver injury, spontaneously develop anti-mitochondrial antibodies (AMA) and have altered hepatocyte mitochondrial size and function. There is no known association of K19 with human disease and no known association of K8/K18/K19 with humanautoimmune liver disease. We tested the hypothesis that K8/K18/K19 variants associate with primary biliary cirrhosis (PBC), an autoimmune cholestatic liver disease characterized by the presence of serum AMA. In doing so, we analyzed the entire exonic regions of K8/K18/K19 in 201 Italian patients and 200 control blood bank donors. Five disease-associated keratin heterozygous variants were identified in patients versus controls (K8 G62C/R341H/V380I, K18R411H, and K19G17S). Four variants were novel and included K19G17S/V229M/N184N and K18R411H. Overall, heterozygous disease-associated keratin variants were found in 17 of 201 (8.5%) PBCpatients and 4 of 200 (2%) blood bank donors (P < 0.004, odds ratio = 4.53, 95% confidence interval = 1.5-13.7). Of the K19 variants, K19G17S was found in three patients but not in controls and all K8 R341H (eight patients and three controls) associated with concurrent presence of the previously described intronic K8 IVS7+10delC deletion. Notably, keratin variants associated with disease severity (12.4% variants in Ludwig stage III/IV versus 4.2% in stages I/II; P < 0.04, odds ratio = 3.25, 95% confidence interval = 1.02-10.40), but not with the presence of AMA. CONCLUSION:K8/K18/K19 variants are overrepresented in Italian PBCpatients and associate with liver disease progression. Therefore, we hypothesize that K8/K18/K19 variants may serve as genetic modifiers in PBC.
Authors: Ildiko Szeverenyi; Andrew J Cassidy; Cheuk Wang Chung; Bernett T K Lee; John E A Common; Stephen C Ogg; Huijia Chen; Shu Yin Sim; Walter L P Goh; Kee Woei Ng; John A Simpson; Li Lian Chee; Goi Hui Eng; Bin Li; Declan P Lunny; Danny Chuon; Aparna Venkatesh; Kian Hoe Khoo; W H Irwin McLean; Yun Ping Lim; E Birgitte Lane Journal: Hum Mutat Date: 2008-03 Impact factor: 4.878
Authors: Michael Hesse; Christine Grund; Harald Herrmann; Dominique Bröhl; Thomas Franz; M Bishr Omary; Thomas M Magin Journal: Exp Cell Res Date: 2007-05-25 Impact factor: 3.905
Authors: Guo-Zhong Tao; Pavel Strnad; Qin Zhou; Ahmad Kamal; Leilei Zhang; Nahid D Madani; Subra Kugathasan; Steven R Brant; Judy H Cho; M Bishr Omary; Richard H Duerr Journal: Clin Gastroenterol Hepatol Date: 2007-05-16 Impact factor: 11.382
Authors: Michele R Stone; Andrea O'Neill; Richard M Lovering; John Strong; Wendy G Resneck; Patrick W Reed; Diana M Toivola; Jeanine A Ursitti; M Bishr Omary; Robert J Bloch Journal: J Cell Sci Date: 2007-10-30 Impact factor: 5.235
Authors: Pavel Strnad; Qin Zhou; Shinichiro Hanada; Laura C Lazzeroni; Bi Hui Zhong; Phillip So; Timothy J Davern; William M Lee; M Bishr Omary Journal: Gastroenterology Date: 2010-06-09 Impact factor: 22.682
Authors: Diana M Toivola; Aida Habtezion; Julia O Misiorek; Linxing Zhang; Joel H Nyström; Orr Sharpe; William H Robinson; Raymond Kwan; M Bishr Omary Journal: FASEB J Date: 2015-09-23 Impact factor: 5.191
Authors: Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason Journal: Gastroenterology Date: 2013-04-10 Impact factor: 22.682